Gilead Sciences Inc (GILD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Gilead Sciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Gilead Sciences Inc's ROI in the second quarter of 2026?
Gilead Sciences Inc had a negative return on investment (ROI) of -7.45%, due to the net loss of $-3 billion, during the twelve months ending in the second quarter of 2026.
Within the Healthcare sector 189 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 309, from total ROI ranking in the first quarter of 2026 at 315.
Gilead Sciences at the Forefront of HIV Research and Investment Dynamics Gilead Sciences, Inc. a prominent player in the pharmaceutical industry, is underlining its commitment to ending the HIV epidemic as it prepares to present significant research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), scheduled for November 10-13. The company is set to unveil results from more than 40 studies focusing on HIV treatment and prevention, including late-breaking clinical data and seven oral presentations. These findings not only highlight Gilead’s robust current portfolio but also signal a future-centric pipeline geared towards person-centered drug development.The upcoming presentations at HIV Glasgow 2024 showcase Gilead s dedication to advancing HIV research and its pivotal role in the therapeutic landscape. These studies underscore a dual focus on both innovative treatment modalities and prevention strategies, reinforcing Gilead’s leadership efforts in tackling the global HIV epidemic. As the landscape of HIV therapy evolves, Gilead’s emphasis on scientifically-backed, patient-oriented solutions positions it as a key stakeholder in the ongoing fight against HIV/AIDS.
Championing Antiviral Innovation: Gilead Sciences at IDWeek 2024 FOSTER CITY, Calif. As the global biotechnology leader Gilead Sciences Inc. prepares to take center stage at IDWeek 2024, anticipation builds around the transformative potential of its antiviral research portfolio. From October 16-19, medical professionals and researchers worldwide will converge to witness Gilead s latest breakthroughs in treating and preventing some of the most challenging viral diseases of our era. With 31 presentations, including a highly anticipated late-breaking abstract and six insightful oral presentations, Gilead is poised to underscore its unwavering commitment to advancing human health and setting new benchmarks in antiviral therapy.The data Gilead is set to unveil covers a broad spectrum of its antiviral initiatives, reflecting its holistic approach to addressing evolving global health challenges. Central to these presentations will be the continued leadership in HIV treatment and prevention. As the fight against HIV persists, Gilead’s innovative methodologies offer renewed hope and practical solutions, highlighting their steadfast resolve to eradicate the disease.
Gilead Sciences Advances HIV Prevention and Cancer Treatment: Promising Developments from Recent Trials and Strategic CollaborationsFOSTER CITY, Calif. In a significant week for Gilead Sciences, Inc. (NASDAQ: GILD), the company announced new findings from its pivotal Phase 3 PURPOSE 2 trial, alongside exciting developments in its strategic collaboration with Genesis Therapeutics, and upcoming presentations highlighting innovative data on Trodelvy (sacituzumab govitecan-hziy) at the IASLC 2024 World Conference on Lung Cancer. Advancements in HIV PreventionAt the 5th HIV Research for Prevention Conference, Gilead presented additional efficacy, safety, and demographic data from the PURPOSE 2 trial (NCT04925752). This landmark study evaluates lenacapavir, Gilead’s twice-yearly injectable HIV-1 capsid inhibitor, specifically aimed at preventing HIV infection among a diverse population of cisgender men and gender-diverse individuals. This new data not only underscores the clinical efficacy of lenacapavir but also highlights Gilead s commitment to addressing health disparities across varied demographic groups. As the rise of HIV continues to affect marginalized communities, the outcomes presented at the conference mark a crucial step toward more accessible and effective preventive measures. The findings are particularly pertinent in light of ongoing public health discussions centered on tailored treatment options in light of demographic diversity.
In a most discerning announcement, the firms of Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have entered into a significant and strategic collaboration aimed at the discovery and development of novel small molecule therapeutics. The proclamation was made today, detailing their joint venture from the flourishing towns of Foster City and Burlingame in the esteemed state of California.Genesis Therapeutics, a vanguard in the realm of artificial intelligence, hath committed itself to the pioneering of generative and predictive technologies with the noble intent of crafting therapeutics for those most formidable of targets. The arrangement will set in motion the utilization of their illustrious AI platform, referred to by the moniker GE, which hath been heralded for its efficacy.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
